Onset CE marks heart valve delivery catheter
This article was originally published in Clinica
Onset Medical has CE marked its SoloPath endovascular access catheter for sale in Europe. The catheter is designed to deliver devices such as heart valves via the femoral and iliac arteries into the larger aortic artery. Up to 20% of patients who require replacement aortic heart valves have severe atherosclerosis in their leg arteries, the Irvine, California firm claims, which may prevent the use of newer percutaneous aortic valves being marketed in Europe by Edwards Lifesciences and Medtronic. In these patients, the valve has to be delivered either through a minimally-invasive incision near the heart or via a totally open-heart surgical procedure. The SoloPath could provide access to these diseased arteries, allowing more patients to be treated with percutaneously implanted aortic heart valves. The SoloPath can also deliver stent grafts for the treatment of aortic aneurysms. Onset expects to launch the SoloPath during the fourth quarter.